Congratulations @SirenBio's SAB member Susan Kaech @Tcellogic on her election to @theNAMedicine for her outstanding scientific and technical achievements in the field of immunology!!!

We gave Léa Bouhelier-Gautreau from @kingscrowdinc a peak into our lab. 🎥 Léa spent a day with our team in San Francisco, watched how our science is done, and spoke with @Nicole_Paulk about where we’re headed. Her verdict on the people doing the work? “Very approachable, very fun, and at the same time extremely professional.” - We’ll take it! 😉 Two FDA-cleared INDs later, that same team is now bringing SRN-101 to the clinic. Watch the visit below. Let’s change the future of cancer care, together. youtube.com/watch?v=wmfmKDmC…

📣 @SirenBio is pleased to announce the appointment of Dr. Peter Bross, MD, former Chief of the Oncology Branch at the FDA’s Center for Biologics Evaluation and Research (CBER), to our Clinical and Scientific Advisory Board! Dr. Bross brings more than 25 years of FDA experience reviewing novel oncology therapies, including gene and cell therapies, immunotherapies, and oncolytic viruses. His expertise comes at an important time as we advance SRN-101, our lead Universal #AAV Immuno #GeneTherapy candidate, into the clinic for recurrent high-grade glioma. Welcome, Dr. Bross! Read more at globenewswire.com/news-relea…

@SirenBio is thrilled to welcome Ford H-Kirschenbaum to our Translational team! Ford brings 30 years of biotech experience building cell-based, biomarker, and bioanalytical assays for preclinical and clinical programs. At Siren, he is the driver of our translational assay development, in our own lab and with our external partners, as SRN-101 moves through the clinic. Welcome to the team, Ford!

🔥 @SirenBio's CEO and Founder @Nicole_Paulk has been named as one of the 2026 @endpts Women in Biopharma! We're so proud to celebrate Nicole's leadership in bringing Universal #AAV Immuno #GeneTherapy to patients with #cancer. Read more: endpoints.news/special-repor… #WomenInBiopharma #Leadership #GeneTherapy #oncology

The @SirenBio team is headed to #Boston this week for Cell & Gene Therapy International @CellTherapyIC! Catch Nathalie Clement and Lauren Kelly on Friday, when they’ll be sharing a behind-the-scenes glimpse of the CMC and nonclinical strategy that led to Siren’s first IND. Don’t miss it!

We’re excited to attend the Cell and Gene Therapy Symposium co-hosted by @UCSD, @CALifeSciences, and @CIRMnews! Our CEO, @Nicole, will be sharing the latest developments at @SirenBio and how we’re advancing #AAV Immuno #GeneTherapy to the clinic. Register & learn more below!👇 genetherapy.ucsd.edu/symposi…

We are thrilled to welcome Mary Bearkland, Senior Director of Clinical Operations, to the @SirenBio team! Mary brings more than 25 years of clinical operations leadership, having directed Phase I–III trials from first-in-human studies to regulatory submission and contributed to two FDA-approved therapies. She will lead our clinical operations as we advance SRN-101, our Universal #AAV Immuno #GeneTherapy, through the clinic. Welcome to the team, Mary!

🎉 Congratulations to Christine Xie on wrapping up a successful summer internship at @SirenBio! Christine, a student at @Stanford, spent the summer generating business development materials that guide Siren's strategic positioning as we advance our Universal #AAV Immuno #GeneTherapy for #Cancer. Her work will continue to serve the team long after her last day. Please join us in congratulating Christine and wishing her all the best as she heads back to Stanford this fall!

September is #ChildhoodCancerAwarenessMonth, and @SirenBio is thinking of every child and family facing a cancer diagnosis. Every step we take to advance Universal #AAV #GeneTherapy for #Cancer is for the patients and families who need better options. Let's sound the alarm against #cancer! #GoldSeptember #GoGold

On #GBMDay 2026, we're thinking of every patient and family living with this disease, and are committed to getting SRN-101 to the people who need it. Let's sound the alarm against #cancer!

📣 BIG news to close out the week! @SirenBio has been awarded an $8M non-dilutive CLIN2 grant from @CIRMnews to support our Phase 1/2 clinical trial of SRN-101 in adult recurrent high-grade glioma! We're incredibly grateful to CIRM and the vision and support of all Californians. Let's sound the alarm against #cancer! Read the press release: globenewswire.com/news-relea…

On #WorldBrainTumorDay, @SirenBio stands with every patient and family living with a brain tumor. Brain tumors like high-grade glioma are among the hardest cancers to treat, and that urgency drives everything we do. We're advancing SRN-101, our #AAV Immuno #GeneTherapy for high-grade glioma, to the clinic for patients who need it most. Let's sound the alarm against #cancer!

As #GrayMay comes to a close, we're reminded of why we show up every day at @SirenBio. High-grade gliomas are among the hardest cancers to treat. Survival is still measured in months for most patients, and meaningful new options have been slow to arrive. There are now two open INDs for SRN-101, our lead asset in recurrent high-grade glioma, and every step forward is motivated by the patients, families, and caregivers facing this disease head-on. Let's sound the alarm against cancer. #GrayMay #BrainTumorAwarenessMonth #GeneTherapy #Cancer

Our team had a wonderful time connecting with collaborators and fellow #AAV #GeneTherapy experts last week at #ASGCT2026! Highlights were talking great science at our annual Siren happy hour and presenting some of our large animal and CMC data. Missed our poster and talk? Check them out on our website: sirenbiotechnology.com/publi…

@SirenBio is headed to #ASGCT2026 next week! Find us at the events below to learn more about our path to the clinic with #SRN101, our lead AAV immuno #genetherapy for #cancer. See you in Boston! Happy Hour RSVP: luma.com/kl56nvvt

BIG moment for @SirenBio 🚨 We’re thrilled to share that our first peer-reviewed manuscript is now published in @CellPressNews Molecular Therapy Oncology - and we’re heading to @ASGCTherapy 2026 with even more data to share! This publication showcases the foundation of our Universal AAV Immuno-Gene Therapy platform, including groundbreaking preclinical data in high-grade glioma, one of the toughest cancers with the greatest unmet need. Huge thanks to our team and collaborators for supporting this work! 👉 Read the full press release here: sirenbiotechnology.com/siren… 👉 Access the open access manuscript here: cell.com/molecular-therapy-f… Want more, like our IND large animal data?! Come find us at #ASGCT2026! #AAV #GeneTherapy #Immunotherapy #Oncology #Publication

Join @SirenBio's CEO @Nicole_Paulk and other industry leaders at the NORD Scientific Symposium next week! We’ll be sharing ways to bring community members in as company stakeholders through community fundraising. Register here: nordscience.org/

Thrilled to see @SirenBio SAB member Beverly Davidson recognized with the Outstanding Achievement Award by @ASGCTherapy! A well-deserved honor celebrating her pioneering work and lasting impact on the field 🌟

Big news for SRN-101 🚀 The FDA has cleared a second IND to launch a Phase 1 trial with SRN-101 in recurrent high-grade glioma. This investigator-initiated study, led by Dr. Nicholas Butowski at @UCSF, marks an exciting step forward in expanding clinical evaluation of SRN-101. We’re so proud to support the UCSF team as they advance this important work for patients in need! Learn more: sirenbiotechnology.com/Siren…